Abstracts Archive - Page 1509 of 2425 - ACR Meeting Abstracts

Abstract Number: 1372 • 2016 ACR/ARHP Annual Meeting
Comparison of the Printo 2010 and Printo/International Myositis and Clinical Studies Group (IMACS) 2016 Improvement Criteria in the Printo Trial in New Onset Juvenile Dermatomyositis
Gabriella Giancane¹, Claudio Lavarello¹, Angela Pistorio¹, Lisa G. Rider¹, Rohit Aggarwal¹, Sheila Oliveira¹, Rubén J. Cuttica¹, Michel Fischbach², Gary Sterba¹, Karine Brochard², Frank Dressler¹, Patrizia Barone¹, Rubén Burgos-Vargas¹, Elizabeth C. Chalom¹, Marine Desjonqueres¹, Graciela Espada¹, Anders Fasth¹, Stella M. Garay¹, Rose-Marie Herbigneaux¹, Claire Hoyoux¹, Chantal Job-deslandre¹, Frederick W. Miller¹, Jiri Vencovsky¹, Angelo Ravelli³, Alberto Martini³ and Nicolino Ruperto⁴, ¹Pediatria II, Reumatologia, PRINTO, Istituto Giannina Gaslini, Genoa, Italy, ²Pediatria II, Reumatologia, PRINTO, Istituto Giannina Gaslini, GENOA, Italy, ³Istituto Giannina Gaslini, Genoa, Italy, ⁴Pediatria II, Reumatologia, Istituto Giannina Gaslini, Genoa, Italy
Background/Purpose: Juvenile dermatomyositis (JDM) is a systemic autoimmune disease characterized by chronic skeletal muscle inflammation with weakness and skin involvement. The Paediatric Rheumatology INternational…
Abstract Number: 1373 • 2016 ACR/ARHP Annual Meeting
Evaluation of the Reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) and Cutaneous Assessment Tool Binary Method (CAT-BM) in Juvenile Dermatomyositis Among Pediatric Dermatologists, Rheumatologists, and Neurologists
Janice Tiao^1,2, Rui Feng³, Emily M. Berger⁴, John F. Brandsema⁵, Carrie C. Coughlin⁶, Neelam Khan², Elizabeth A. Kichula⁵, Melissa A. Lerman⁷, Svetlana Lvovich⁸, Patrick J. McMahon⁹, Lisa G. Rider¹⁰, Adam I. Rubin², Lisabeth V. Scalzi¹¹, Douglas M. Smith⁵, Alysha J. Taxter¹², James R. Treat⁹, Ryan P. Williams¹³, Sabrina W. Yum⁵, Joyce Okawa² and Victoria P. Werth^1,2, ¹Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, ²Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ³Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, ⁴Hackensack University Medical Center, Hackensack, NJ, ⁵Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, ⁶Division of Dermatology, Washington University School of Medicine, St. Louis, MO, ⁷Division of Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ⁸St. Christopher's Hospital for Children, Philadelphia, PA, ⁹Division of Dermatology, Children's Hospital of Philadelphia, Philadelphia, PA, ¹⁰Environmental Autoimmunity Group, Program of Clinical Research, National Institute of Environmental Health Sciences, National Institutes of Health, US Department of Health and Human Services, Bethesda, MD, ¹¹Department of Rheumatology, Penn State Hershey Children’s Hospital, Hershey, PA, ¹²Pediatrics, Brenner Children's Hospital, Wake Forest Baptist Medical Center, Winston-Salem, NC, ¹³Minneapolis Clinic of Neurology, Maple Grove, MN
Background/Purpose: The Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) and Cutaneous Assessment Tool-Binary Method (CAT-BM) have been shown to be reliable and valid outcome…
Abstract Number: 1374 • 2016 ACR/ARHP Annual Meeting
Predictors of Changes in Disease Activity Among Children with Juvenile Dermatomyositis
Cynthia S. Crowson¹, Jeannette M. Olazagasti Lourido², Timothy B. Niewold³, Ann M Reed⁴ and CARRA Investigators, ¹Health Sciences Research, Mayo Clinic, Rochester, MN, ²University of Puerto Rico, San Juan, Puerto Rico, ³Rheumatology and Immunology, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Duke University, Durham, NC
Background/Purpose: Determinants of changes in disease activity among patients with juvenile dermatomyositis (JDM) are unknown. Our objective was to develop scores to predict changes in…
Abstract Number: 1375 • 2016 ACR/ARHP Annual Meeting
A Five Year Study of 102 Children with Juvenile Myositis: Disease Course and Outcomes
Lauren M. Pachman^1,2,3, Megan L. Curran⁴, Gabrielle A. Morgan^5,6, Maria C. Amoruso^1,7, Ira N. Targoff^8,9 and Chiang-Ching Huang¹⁰, ¹Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ²Pediatric Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Rheumatology/Immunology, Ann & Robert H. Lurie Children's Hosptial of Chicago, Chicago, IL, ⁴Division of Rheumatology, Department of Pediatrics, Ann & Robert H. Lurie Children’s Hospital of Chicago/Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Cure JM Program of Excellence in Myositis Research, Chicago, IL, ⁶Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁷Immunology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁸Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁹University of Oklahoma, Oklahoma City, OK, ¹⁰Zilber School of Public Health, University of Wisconsin, Milwaukee, Milwaukee, WI
Background/Purpose: Children with juvenile myositis (JM) have a variable disease course, in part associated with myositis specific/associated antibodies (MSA). Time to off medications has not…
Abstract Number: 1376 • 2016 ACR/ARHP Annual Meeting
In Juvenile Dermatomyositis, Organ Damage Is Comparable after Median 13.5 and 21.5 Years Follow-up Time, Despite Sustained Disease Activity
Kristin Schjander Berntsen¹, Berit Flatø^1,2, Ivar Sjaastad^2,3 and Helga Sanner^1,4, ¹Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, Oslo, Norway, ²Institute for Clinical Medicine, University of Oslo, Oslo, Norway, Oslo, Norway, ³Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway, Oslo, Norway, ⁴Norwegian National Advisory Unit on Rheumatic Diseases in Children and Adolescents, Oslo University Hospital, Rikshospitalet, Oslo, Norway, Oslo, Norway
Background/Purpose: All previous studies of disease outcome in juvenile dermatomyositis (JDM) patients have been based on retrospective data or cross sectional examination. We aimed to…
Abstract Number: 1377 • 2016 ACR/ARHP Annual Meeting
The Role of Muscle MRI in Detecting a Flare-up of Juvenile Dermatomyositis
Rabheh Abdul Aziz¹, Charles H. Spencer², Sharon M. Bout-Tabaku³, CHACK-YUNG Yu⁴, Brent Adler⁵, Katherine Lintner⁶ and Melissa Moore-Clingenpeel⁷, ¹pediatric Rheumatology, Nationwide Children's Hospital, Columbus, OH, ²Rheumatology, Nationwide Childrens Hospital/OSU, Columbus, OH, ³Rheumatology, Nationwide Children's Hospital, Columbus, OH, ⁴Research, Nationwide Children's Hospital, Columbus, OH, ⁵Radiology, Nationwide Children's Hospital, Columbus, OH, ⁶The Research Institute at Nationwide Children's Hospital and The Ohio State University, Columbus, OH, ⁷Research, Nationwide Children's Hospital, Dublin, OH
Background/Purpose
Abstract Number: 1378 • 2016 ACR/ARHP Annual Meeting
Pentraxin-3 Level Predicts Vasculitis and Mucocutaneous Involvement in Childhood-Onset Systemic Lupus Erythematosus
Sezgin Sahin¹, Amra Adrovic¹, Kenan Barut¹, Sinem Durmus², Hafize Uzun² and Ozgur Kasapcopur³, ¹Pediatric Rheumatology, Istanbul University, Cerrahpasa Medical School, Department of Pediatric Rheumatology, Istanbul, Turkey, ²Biochemistry, Istanbul University, Cerrahpasa Medical School, Department of Biochemistry, Istanbul, Turkey, ³Department of Pediatric Rheumatology, Istanbul University, Cerrahpasa Medical School, Department of Pediatric Rheumatology, Istanbul, Turkey
Background/Purpose: Systemic lupus erythematosus (SLE) is a persistent or remitting-relapsing autoimmune disease that handled in the context of connective tissue diseases and also vasculitides. Although…
Abstract Number: 1379 • 2016 ACR/ARHP Annual Meeting
Evaluation of S100 Proteins As Potential Biomarkers of Global and Renal-Specific Disease Activity in Childhood-Onset Systemic Lupus Erythematosus
Jessica Turnier¹, Ndate Fall², Sherry Thornton², Alexei Grom^2,3 and Hermine I. Brunner^4,5, ¹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³PRCSG, Cincinnati, OH, ⁴Cincinnati Children's Hospital Medical Center, PRCSG, Cincinnati, OH, ⁵Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) is a heterogeneous disease with differing levels of disease activity and organ-specific disease manifestations in each individual. In particular,…
Abstract Number: 1380 • 2016 ACR/ARHP Annual Meeting
Multicenter Prospective Study on the Role of Urinary HER2 As a Lupus Nephritis Biomarker
Patrícia Costa Reis¹, Kelly Maurer², Emily von Scheven³, Kathleen O'Neil⁴, Jon M. Burnham⁵, Laura E. Schanberg⁶, Michelle Petri⁷ and Kathleen E. Sullivan⁸, ¹Division of Allergy and Immunology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Immunology ARC 1216, The Children's Hospital of Philadelphia, Philadelphia, PA, ³Division of Rheumatology, Department of Pediatrics, University of California, San Francisco, San Francisco, CA, ⁴Pediatrics, Indiana University, Indianapolis, IN, ⁵Pediatric Rheumatology, Children's Hospital Philadelphia, Philadelphia, PA, ⁶Pediatrics, Duke Medical Center, Durham, NC, ⁷Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ⁸Allergy Immunology, The Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: HER2 (Human Epidermal Growth Factor Receptor 2) is dramatically overexpressed in the glomeruli and in the tubular compartment of patients with lupus nephritis, but…
Abstract Number: 1381 • 2016 ACR/ARHP Annual Meeting
Humoral Immune Response and Cytokine Profile after a Booster Dose with Tdap Vaccine in Juvenile Systemic Lupus Erythematosus and Controls
Octavio Peracchi¹, Aline Nicacio², Fernanda Spina³, Juliana Yamada³, Brunna Alvarenga³, Maria Isabel Pinto³ and Maria Teresa Terreri⁴, ¹Pediatric Rheumatology, Federal University of Sao Paulo, Department of Pediatrics, Sao Paulo, Brazil, Sao Paulo, Brazil, ²Pediatric Rheumatology Unit, Department of Pediatrics, Federal University of Sao Paulo, Sao Paulo, Brazil, Sao Paulo, Brazil, ³Federal University of Sao Paulo, Department of Pediatrics, Sao Paulo, Brazil, Sao Paulo, Brazil, ⁴Pediatric Rheumatology Unit, Federal University of São Paulo, São Paulo, Brazil
Background/Purpose: Pertussis cases have increased worldwide and knowledge on immune response and cytokine profile after adult Tdap vaccine is scarce. This study evaluated the humoral…
Abstract Number: 1382 • 2016 ACR/ARHP Annual Meeting
Effect of Lupus Anticoagulant on Rotational Thromboelastometry in Juvenile Systemic Lupus Erythematosus: Preliminary Data on a Single Center Cohort
Maria Pereira¹, Eyal Muscal², Lisa Hensch³, Vadim Kostousov³, Karen Bruzdoski³, Shiu-Ki Hui³, Jun Teruya³ and Marietta DeGuzman¹, ¹Allergy, Immunology and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Immunology, allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ³Pathology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Interpretation of coagulation tests remain a challenge in jSLE with positive aPL. Lupus anticoagulant (LA) can mimic bleeding diathesis and its effect on prolonged…
Abstract Number: 1383 • 2016 ACR/ARHP Annual Meeting
ANTI-RO/SSA and/or ANTI-La/SSB Antibodies: Association with Mild LUPUS Manifestations in 645 Childhood-Onset Systemic LUPUS Erythematosus
Glaucia V. Novak¹, Mariana Marques², Verena Balbi², Natali W. Gormezano², Katia T. Kozu², Ana Paula Sakamoto³, Rosa M R Pereira⁴, Maria Teresa Terreri³, Claudia S. Magalhães⁵, Silvana B. Sacchetti Sr.⁶, Adriana M E Sallum², Roberto Marini Sr.⁷, Virgínia Ferriani⁸, Cássia M. Barbosa⁹, Tânia C M Castro¹⁰, Valéria C. Ramos¹¹, Eloisa Bonfá¹² and Clovis A Silva¹³, ¹Pediatric Rheumatology Unit,, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Pediatric Rheumatology Unit, University of São Paulo, São Paulo, Brazil, ³Pediatric Rheumatology Unit, Federal University of São Paulo, São Paulo, Brazil, ⁴Rheumatology, University of São Paulo, São Paulo, Brazil, ⁵Pediatric Rheumatology Division, São Paulo State University (UNESP), Botucatu, Brazil, ⁶Pediatric Rheumatology Unit, Irmandade da Santa Casa de Misericórdia de São Paulo, São Paulo, Brazil, ⁷Pediatric Rheumatology Unit, State University of Campinas, São Paulo, Brazil, ⁸Department of Pediatrics School of Medicine of Ribeirão Preto, University of São Paulo (USP-RP), Ribeirão Preto, Brazil, ⁹Pediatric Rheumatology Unit, Hospital Infantil Darcy Vargas, São Paulo, Brazil, ¹⁰Pediatric Rheumatology Unit, Hospital Menino Jesus, São Paulo, Brazil, ¹¹Pediatric Rheumatology Unit, Pontifical Catholic University of Sorocaba, São Paulo, Brazil, ¹²Rheumatology, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ¹³Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Anti-Ro/SSA and anti-La/SSB antibodies were reported in 30-50% and 10-30% of adult SLE patients, associated mainly with cutaneous manifestations. However, to our knowledge there…
Abstract Number: 1384 • 2016 ACR/ARHP Annual Meeting
Comparison of the Systemic Lupus Collaborating Clinics-Damage Index Score with a Physician Global Assessment of Damage in an International Cohort of Patients with Childhood-Onset Systemic Lupus
Michael J. Holland¹, Jun Ying², Nicolino Ruperto^3,4, Kasha Wiley¹, Earl Silverman⁵ and Hermine I. Brunner¹, ¹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Center for Biostatistical Services, University of Cincinnati College of Medicine, Cincinnati, OH, ³Pediatria II, Reumatologia, Istituto Giannina Gaslini, Genoa, Italy, ⁴Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genoa, Italy, ⁵Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) is a chronic autoimmune disease, which can affect any organ system. cSLE is associated with significant morbidity, including…
Abstract Number: 1385 • 2016 ACR/ARHP Annual Meeting
Frequency of the Systemic Lupus Collaborating Clinics- Damage Index Items in Three Registries of Childhood-Onset Systemic Lupus Erythematosus
Michael J. Holland¹, Michael W. Beresford^2,3,4, Nicolino Ruperto⁵, Allen Watts¹, Kasha Wiley¹, Elisabetta Cortis^5,6, Seza Ozen^5,7, Oscar Porras^5,8, Flavio Sztajnbok^5,9, Maria Apaz^5,10 and Hermine I. Brunner¹, ¹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust Hospital, Liverpool, United Kingdom, ³Alder Hey Children's NHS Foundation Trust Hospital, Institute of Translational Medicine (Child Health), University of Liverpool, Liverpool, United Kingdom, ⁴On Behalf of the UK JSLE Study Group, Liverpool, United Kingdom, ⁵Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genoa, Italy, ⁶Santa Maria della Stella Hospital, Orvieto, Italy, ⁷Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁸Hospital Nacional de Niños, San Jose, Costa Rica, ⁹Pediatric Rheumatology Division, Adolescent Health Care Unit, Universida de do Estado do Rio de Janeiro., Rio de Janeiro, Brazil, ¹⁰Pediatric Rheumatology, Hospital de Niños de Cordoba, Córdoba, Argentina
Background/Purpose: Childhood-Onset Systemic Lupus Erythematosus (cSLE) is a chronic, multi-system autoimmune disease. In addition to active inflammation, cSLE may result in irreversible damage to affected…
Abstract Number: 1386 • 2016 ACR/ARHP Annual Meeting
Outcome of 847 Childhood-Onset Systemic LUPUS Erythematousus Patients in Three Age Groups
Sandra R M Lopes¹, Natali W. Gormezano², Roberta C. Gomes Sr.³, Nadia E Aikawa⁴, Rosa M R Pereira⁵, Maria Teresa Terreri⁶, Claudia S. Magalhães⁷, Eunice M. Okuda⁸, Ana Paula Sakamoto⁶, Adriana M E Sallum², Simone Appenzeller⁹, Virgínia Ferriani¹⁰, Cássia M. Barbosa¹¹, Simone Lotufo¹², Adriana A. Jesus^13,14, Luis E C Andrade¹⁵, Lucia M A Campos⁴, Eloisa Bonfa¹⁶ and Clovis A Silva³, ¹Division of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Pediatric Rheumatology Unit, University of São Paulo, São Paulo, Brazil, ³Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Pediatric Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁵Rheumatology Division, Rheumatology Division, Faculdade de Medicina da USP, São Paulo, Brazil, ⁶Pediatric Rheumatology Unit, Federal University of São Paulo, São Paulo, Brazil, ⁷Pediatric Rheumatology Division, São Paulo State University (UNESP), Botucatu, Brazil, ⁸Pediatric Rheumatology Unit, Irmandade da Santa Casa de Misericórdia de São Paulo, São Paulo, Brazil, ⁹Pediatric Rheumatology Unit, State University of Campinas, Campinas, Brazil, ¹⁰Department of Pediatrics School of Medicine of Ribeirão Preto, University of São Paulo (USP-RP), Ribeirão Preto, Brazil, ¹¹Pediatric Rheumatology Unit, Hospital Infantil Darcy Vargas, São Paulo, Brazil, ¹²Pediatric Rheumatology Unit, Hospital Municipal Infantil Menino Jesus, São Paulo, Brazil, ¹³Pediatrics Department, Universidade de São Paulo, São Paulo, Brazil, ¹⁴Pediatrics, Instituto da Criança da Faculdade de Medicina da Universidade de São Paulo (FMUSP), Sao Paulo, Brazil, ¹⁵Pediatric Rheumatology Unit, Universidade Federal de São Paulo, São Paulo, Brazil, ¹⁶Rheumatology Divison, Hospital das Clinicas, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil
Background/Purpose: A recent large study comparing childhood systemic lupus erythematosus (cSLE) with adult-onset SLE revealed a more aggressive and worse outcome in the former group.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].